PMID- 30039930
OWN - NLM
STAT- MEDLINE
DCOM- 20190110
LR  - 20211204
IS  - 2055-5822 (Electronic)
IS  - 2055-5822 (Linking)
VI  - 5
IP  - 5
DP  - 2018 Oct
TI  - Sacubitril-valsartan in heart failure and multimorbidity patients.
PG  - 956-959
LID - 10.1002/ehf2.12338 [doi]
AB  - AIMS: The poor control of symptoms in patients with advanced heart failure with 
      reduced ejection function (HFrEF) can limit the functionality of patients. 
      Sacubitril-valsartan, compared with enalapril, has been shown to reduce mortality 
      and hospitalization, and nowadays, there is still little evidence about the 
      improvement on functionality. The aim of our study is to analyse the improvement 
      of the functional class and the 6 min walking test (6MWT) in patients with 
      multiple pathologies and advanced heart failure. METHODS AND RESULTS: From 
      September 2016 to March 2018, 65 multimorbidity patients with severe symptomatic 
      HFrEF were initiated to receive sacubitril-valsartan. Mean age was 
      78.6 +/- 7.4 years, and 68% were male. The Charlson co-morbidity index was 8 
      points. Seventy-four per cent had New York Heart Association (NYHA) Functional 
      Class IV. After the treatment, patients were able to achieve 55.68 m or more on 
      6MWT, and 91% presented an improvement in the NYHA functional class. CONCLUSIONS: 
      Sacubitril-valsartan relieves symptoms and improves functional class prognostic 
      risk of patients with advanced HFrEF and co-morbidity.
CI  - (c) 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on 
      behalf of the European Society of Cardiology.
FAU - Rodil Fraile, Raquel
AU  - Rodil Fraile R
AUID- ORCID: 0000-0001-9868-8066
AD  - Internal Medicine Department, Chronic-Multimorbidity Unit, Complejo Hospitalario 
      de Navarra, Irunlarrea, 34, 31008, Pamplona, Spain.
FAU - Malafarina, Vincenzo
AU  - Malafarina V
AD  - Geriatric Department, Chronic-Multimorbidity Unit, Complejo Hospitalario de 
      Navarra, Irunlarrea, 34, 31008, Pamplona, Spain.
AD  - Department of Nutrition, Food Science and Physiology, Faculty of Pharmacy and 
      Nutrition, University of Navarra, 31008, Pamplona, Spain.
FAU - Tiberio Lopez, Gregorio
AU  - Tiberio Lopez G
AD  - Internal Medicine Department, Chronic-Multimorbidity Unit, Complejo Hospitalario 
      de Navarra, Irunlarrea, 34, 31008, Pamplona, Spain.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20180724
PL  - England
TA  - ESC Heart Fail
JT  - ESC heart failure
JID - 101669191
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Tetrazoles)
RN  - 80M03YXJ7I (Valsartan)
RN  - EC 3.4.24.11 (Neprilysin)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
CIN - ESC Heart Fail. 2019 Oct;6(5):1096. PMID: 31420966
CIN - ESC Heart Fail. 2019 Oct;6(5):1097-1098. PMID: 31420974
MH  - Aged
MH  - Aminobutyrates/*therapeutic use
MH  - Angiotensin Receptor Antagonists/therapeutic use
MH  - Biphenyl Compounds
MH  - Comorbidity
MH  - Drug Combinations
MH  - Female
MH  - Heart Failure/*drug therapy/epidemiology
MH  - Humans
MH  - Male
MH  - Neprilysin
MH  - Retrospective Studies
MH  - Tetrazoles/*therapeutic use
MH  - Treatment Outcome
MH  - Valsartan
PMC - PMC6165940
OTO - NOTNLM
OT  - Elderly
OT  - MAGGIC score
OT  - Multimorbidity
OT  - NYHA
OT  - Sacubitril-valsartan
OT  - Six-minute walking test
EDAT- 2018/07/25 06:00
MHDA- 2019/01/11 06:00
PMCR- 2018/07/24
CRDT- 2018/07/25 06:00
PHST- 2018/05/16 00:00 [received]
PHST- 2018/06/22 00:00 [accepted]
PHST- 2018/07/25 06:00 [pubmed]
PHST- 2019/01/11 06:00 [medline]
PHST- 2018/07/25 06:00 [entrez]
PHST- 2018/07/24 00:00 [pmc-release]
AID - EHF212338 [pii]
AID - 10.1002/ehf2.12338 [doi]
PST - ppublish
SO  - ESC Heart Fail. 2018 Oct;5(5):956-959. doi: 10.1002/ehf2.12338. Epub 2018 Jul 24.